152 related articles for article (PubMed ID: 15140332)
1. Burden of illness of hepatitis C from a managed care organization perspective.
Armstrong EP; Charland SL
Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
[TBL] [Abstract][Full Text] [Related]
2. Population-based hepatitis C surveillance and treatment in a national managed care organization.
Shatin D; Schech SD; Patel K; McHutchison JG
Am J Manag Care; 2004 Apr; 10(4):250-6. PubMed ID: 15124501
[TBL] [Abstract][Full Text] [Related]
3. Cost of atrial fibrillation in United States managed care organizations.
Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
[TBL] [Abstract][Full Text] [Related]
4. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
Shah M; Butler M; Bramley T; Curtice TG; Fine S
Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C.
Markowitz JS; Gutterman EM; Hodes D; Klaskala W
J Viral Hepat; 2005 Mar; 12(2):176-85. PubMed ID: 15720533
[TBL] [Abstract][Full Text] [Related]
6. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
[TBL] [Abstract][Full Text] [Related]
8. Direct costs of blindness experienced by patients enrolled in managed care.
Frick KD; Walt JG; Chiang TH; Doyle JJ; Stern LS; Katz LM; Dolgitser M; Hendlish SK
Ophthalmology; 2008 Jan; 115(1):11-7. PubMed ID: 17475331
[TBL] [Abstract][Full Text] [Related]
9. Cost associated with the treatment of influenza in a managed care setting.
Cox F; Khan ZM; Schweinle JE; Okamoto L; McLaughlin T
MedGenMed; 2000 Oct; 2(4):E34. PubMed ID: 11104480
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
11. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
13. [Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
Reiser M; Haverkamp A; Dintsios M; Mölleken C; Krauth C; Pieper W; Schmiegel W
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1743-7. PubMed ID: 17713882
[TBL] [Abstract][Full Text] [Related]
14. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand.
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2003 Jun; 22(2):159-67. PubMed ID: 12850902
[TBL] [Abstract][Full Text] [Related]
15. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
[TBL] [Abstract][Full Text] [Related]
16. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection.
Hare CB; Morris JA; Chu A; Gotz V; Loveland JJ; Hodes D; Klaskala W
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):71-6. PubMed ID: 16136612
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
18. Comparing total health care costs and treatment patterns of HIV patients in a managed care setting.
Purdum AG; Johnson KA; Globe DR
AIDS Care; 2004 Aug; 16(6):767-80. PubMed ID: 15370064
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study.
Sungkanuparph S; Vibhagool A; Manosuthi W; Kiertiburanakul S; Atamasirikul K; Aumkhyan A; Thakkinstian A
J Med Assoc Thai; 2004 Nov; 87(11):1349-54. PubMed ID: 15825712
[TBL] [Abstract][Full Text] [Related]
20. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Lu S; Hill J; Fillit H
Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
